NASDAQ:AMGN - Amgen Stock Price, Forecast & News

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen announced a quarterly dividend on Wednesday, December 11th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.60 per share on Friday, March 6th. This represents a $6.40 dividend on an annualized basis and a yield of 2.65%. The ex-dividend date is Thursday, February 13th. This is a positive change from Amgen's previous quarterly dividend of $1.45. View Amgen's Dividend History.

Amgen announced that its board has authorized a stock buyback program on Friday, February 2nd 2018, which permits the company to buyback $10,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company's board believes its shares are undervalued.

Amgen, Inc. (NASDAQ:AMGN) posted its quarterly earnings results on Tuesday, October, 29th. The medical research company reported $3.66 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $3.53 by $0.13. The medical research company earned $5.74 billion during the quarter, compared to analysts' expectations of $5.63 billion. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The company's revenue for the quarter was down 2.8% on a year-over-year basis. During the same period last year, the firm earned $3.69 earnings per share. View Amgen's Earnings History.

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for Amgen.

Amgen will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Amgen issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of $$14.50-14.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $$14.44. The company issued revenue guidance of $$23.1-23.3 billion, compared to the consensus revenue estimate of $$23.01 billion.

21 brokerages have issued 12-month price targets for Amgen's shares. Their forecasts range from $198.00 to $277.00. On average, they expect Amgen's stock price to reach $236.29 in the next twelve months. This suggests that the stock has a possible downside of 2.2%. View Analyst Price Targets for Amgen.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amgen.

News stories about AMGN stock have trended very negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amgen earned a media sentiment score of -3.8 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Amgen.

Amgen saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 9,910,000 shares, an increase of 8.2% from the December 15th total of 9,160,000 shares. Based on an average daily volume of 2,130,000 shares, the short-interest ratio is currently 4.7 days. Approximately 1.7% of the company's stock are sold short. View Amgen's Current Options Chain.

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Alibaba Group (BABA), NVIDIA (NVDA), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), AT&T (T), Home Depot (HD), JPMorgan Chase & Co. (JPM) and Gilead Sciences (GILD).

Amgen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Johanson Financial Advisors Inc. (0.20%), PGGM Investments (0.09%), Douglass Winthrop Advisors LLC (0.05%), Nisa Investment Advisors LLC (0.05%), Gateway Investment Advisers LLC (0.05%) and Manning & Napier Group LLC (0.03%). Company insiders that own Amgen stock include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including PGGM Investments, Commerzbank Aktiengesellschaft FI, Gateway Investment Advisers LLC, Tocqueville Asset Management L.P., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Creative Financial Designs Inc. ADV, State of Alaska Department of Revenue and Nisa Investment Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David W Meline, Jonathan P Graham, R Sanders Williams and Ronald D Sugar. View Insider Buying and Selling for Amgen.

AMGN stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., DNB Asset Management AS, Manning & Napier Group LLC, Fluent Financial LLC, Camelot Portfolios LLC, Sanders Morris Harris LLC, Private Trust Co. NA and Alpha Cubed Investments LLC. View Insider Buying and Selling for Amgen.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMGN stock can currently be purchased for approximately $241.49.

Amgen has a market capitalization of $143.49 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.View Additional Information About Amgen.

The official website for Amgen is http://www.amgen.com/.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]